Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

被引：0
作者：
Michael Guger
Christian Enzinger
Fritz Leutmezer
Franziska Di Pauli
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
机构：
[1] Kepler University Hospital GmbH,Clinic for Neurology 2, Med Campus III
[2] Johannes Kepler University Linz,Medical Faculty
[3] Medical University of Graz,Department of Neurology
[4] Medical University of Vienna,Department of Neurology
[5] Medical University of Innsbruck,Clinical Department of Neurology
[6] Paracelsus Medical University and Salzburger Landeskliniken,Department of Laboratory Medicine
[7] Heinrich-Heine-University,Department of Neurology, Medical Faculty
[8] Hermesoft,undefined
[9] Data management,undefined
[10] Hermesoft,undefined
[11] Statistics,undefined
来源：
Journal of Neurology | 2021年 / 268卷
关键词：
Disability progression; Long-term; Multiple sclerosis; Natalizumab; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4303 / 4310
页数：7
相关论文
共 50 条
  • [1] Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Di Pauli, Franziska
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2021, 268 (11) : 4303 - 4310
  • [2] Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
    van Lierop, Zoe Y. G. J.
    Wieske, Luuk
    Koel-Simmelink, Marleen J. A.
    Chatterjee, Madhurima
    Dekker, Iris
    Leurs, Cyra E.
    Willemse, Eline A. J.
    Moraal, Bastiaan
    Barkhof, Frederik
    Eftimov, Filip
    Uitdehaag, Bernhard M. J.
    Killestein, Joep
    Teunissen, Charlotte E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (01) : 102 - 110
  • [3] Long-term outcome in multiple sclerosis patients treated with fingolimod
    Lattanzi, Simona
    Rocchi, Chiara
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carletti, Stella
    Silvestrini, Mauro
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 45
  • [4] Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis
    Prosperini, Luca
    Fanelli, Fulvia
    Pozzilli, Carlo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 364 : 145 - 147
  • [5] Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
    Clerico, Marinella
    Artusi, Carlo Alberto
    Di Liberto, Alessandra
    Rolla, Simona
    Bardina, Valentina
    Barbero, Pierangelo
    De Mercanti, Stefania Federica
    Durelli, Luca
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 963 - 972
  • [6] Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
    Dekker, I
    Leurs, C. E.
    Hagens, M. H. J.
    van Kempen, Z. L. E.
    Kleerekooper, I
    Lissenberg-Witte, B., I
    Barkhof, F.
    Uitdehaag, B. M. J.
    Balk, L. J.
    Wattjes, M. P.
    Killestein, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 82 - 87
  • [7] Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2019, 266 (11) : 2672 - 2677
  • [8] Natalizumab in Multiple Sclerosis: Long-Term Management
    Clerico, Marinella
    Artusi, Carlo Alberto
    Di Liberto, Alessandra
    Rolla, Simona
    Bardina, Valentina
    Barbero, Pierangelo
    De Mercanti, Stefania Federica
    Durelli, Luca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [9] Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
    Kaufmann, Maxi
    Haase, Rocco
    Proschmann, Undine
    Ziemssen, Tjalf
    Akguen, Kafja
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [10] Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
    van Lierop, Zoe Y. G. J.
    Noteboom, Samantha
    Steenwijk, Martijn D.
    van Dam, Maureen
    Toorop, Alyssa A.
    Kempen, Zoe L. E. van
    Moraal, Bastiaan
    Barkhof, Frederik
    Uitdehaag, Bernard M. J.
    Schoonheim, Menno M.
    Teunissen, Charlotte E.
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (14) : 2231 - 2242
12345